Home / World Marketplace / Archive by category Global Health & Biotech (Page 47)

Archive by category Global Health & Biotech

Samsung Bioepis and Teva Enter into a Strategic Partnership for Commercialization of EPYSQLI® (eculizumab-aagh) in the United States

Marks a step forward in broadening treatment options for patients with paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS) and generalized myasthenia gravis (gMG) in the U.S. Partnership supports Teva’s Pivot to Growth strategy and adds to its broad biosimilar portfolio INCHEON, Korea and TEL AVIV, Israel, Jan. 10, 2025 (Korea Bizwire) – Samsung Bioepis Co., Ltd. and Teva Pharmaceutical Industries Ltd. [...]

Philips appoints Jie Xue as Chief Business Leader Precision Diagnosis, co-leader of the Diagnosis & Treatment segment, and Özlem Fidanci as Chief of International Region

January 9, 2025 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the appointment of Jie Xue as Chief Business Leader Precision Diagnosis, and Özlem Fidanci as Chief of International Region, both effective January 1, 2025. Ms. Xue and Ms. Fidanci have joined Philips’ Executive Committee and report directly [...]

Primo Partners with SHINE to Advance Precision Cancer Care in Asia-Pacific

Partnership Delivers Advanced Radioligand Treatments Across Asia-Pacific, Expanding Access to Cutting-Edge Cancer Therapies TAIPEI, Taiwan, Jan. 8 (Korea Bizwire) — Primo Biotechnology (“Primo”) today announced a strategic partnership with SHINE Technologies, LLC, (“SHINE”) a global leader in nuclear medicine production. The partnership includes a supply and exclusive distribution agreement to introduce Ilumira (n.c.a. lutetium-177, Lu-177), [...]

Zymeworks Outlines Strategic Priorities and Outlook for 2025 and 2026

Investigational new drug (IND) applications for initiating first-in-human studies for ZW220 and ZW251 in solid tumors anticipated in 2025 IND applications for initiating first-in-human studies for ZW209 and ZW1528 anticipated in 2026 Phase 3 HERIZON-GEA-01 top-line results for Ziihera® (zanidatamab-hrii) in first-line HER2-positive gastroesophageal adenocarcinoma (GEA) are expected 2Q-2025, with potential supplemental biologics license application (sBLA) [...]

Hummingbird Bioscience Licenses Novel Antibodies to Immunome

SAN FRANCISCO and SINGAPORE, Jan. 07, 2025 (Korea Bizwire) – Hummingbird Bioscience, a precision biotherapeutics company discovering and developing transformative biologics for hard-to-treat diseases, today announced it has granted Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, an exclusive, worldwide license to monoclonal antibodies that are directed [...]

iHerb Debuts Digital Wellness Hub to Empower Personal Health Goals

Complimentary online resource offers over 1,200 informative articles, recipes, videos and podcasts from numerous wellness experts and translated in 14 languages IRVINE, Calif., Jan. 2 (Korea Bizwire) – iHerb, one of the world’s leading online retailers for vitamins, minerals, supplements and other health and wellness products, today announced the launch of its iHerb Wellness [...]

Teva to Present at the 43rd Annual J.P. Morgan Healthcare Conference

TEL AVIV, Israel, Dec. 23, 2024 (Korea Bizwire) – Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva’s President and CEO, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025. The presentation will begin at 8:15 A.M. Pacific Time (11:15 A.M. Eastern Time). To access [...]

Scientists report studies showing a novel drug repairs myelin and restores nervous system function in a model of multiple sclerosis

HALIFAX, Nova Scotia and SPRING, Texas, Dec. 23, 2024 (Korea Bizwire) – Scientists at Dalhousie University in Halifax, and Io Therapeutics, Inc. in Spring Texas, announced today collaborative publication of data from studies demonstrating effectiveness of the RXR agonist compound IRX4204 in reversing demyelination, and functionally restoring movement in the paralyzed legs of mice subjected [...]

Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and 2025 Financial Guidance at 8 a.m. ET on January 29, 2025

TEL AVIV, Israel, Dec. 20, 2024 (Korea Bizwire) – Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its fourth quarter and full year 2024 financial results, as well as on its financial guidance for 2025, on Wednesday, January 29, 2025, at 7:00 a.m. ET. Following the [...]

Publication relating to transparency notifications: Nyxoah

REGULATED INFORMATION Mont-Saint-Guibert (Belgium), December 20, 2024, 10:30 pm CET / 4:30 pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below. BlackRock, Inc. On December 19, 2024, Nyxoah received a transparency notification from BlackRock, [...]